Under construction – not a live service
Sign in
Not yet taking people in TaiwanPhase 2

Tests pumitamig before surgery for early-stage lung cancer

Tests pumitamig-based treatment before surgery in adults with early-stage non-small cell lung cancer.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Taichung, Tainan, and Taipei, TaiwanSee the 4 sitesAlso in 13 other countries, 46 sites
Trial code
Registry title
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Status
Not yet recruiting
Phase
Phase 2
People taking part
80 people, planned
Starts
30 Nov 2026
Expected to end
15 Mar 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Pumitamig
  • Carboplatin
  • Cisplatin
  • Paclitaxel
  • Pemetrexed
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed lung cancer (non-small cell type) that has not been treated and can be removed by surgery. Treatment is given before the operation.

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-small cell lung cancer, squamous or non-squamous, that can be removed by surgery, Stage IIA to IIIB (N2)
Earlier treatment
Must not have had any earlier cancer drug treatment, radiotherapy or investigational treatment for this lung cancer
Biomarker or test result
PD-L1 level must be measurable

Main reasons for not taking part

  • Cancer that cannot be removed by surgery, N3 lymph node spread, or spread to distant organs
  • Active autoimmune disease
  • Serious heart problems
  • Serious lung disease, or past or current interstitial lung disease or pneumonitis needing steroid treatment
  • High risk of bleeding, or a gut fistula, gut perforation or abscess in the abdomen

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Participants must have newly diagnosed, previously untreated participants with histologically confirmed non-small cell lung cancer (NSCLC) (squamous or non-squamous histology); resectable Stage IIA to IIIB (N2) disease (American Joint Committee on Cancer (AJCC) 9th edition)
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Participants must have an evaluable programmed death-ligand 1 (PD-L1) expression

Who cannot take part

  • Participants must not have significant cardiovascular impairment as evidenced by uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias or major thrombotic or embolic events
  • Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or who have current or suspected ILD or pneumonitis
  • Participants must not have prior systemic anticancer therapy, radiotherapy, or investigational therapy for NSCLC or contraindication to curative-intent surgery or study-specified chemotherapy
  • Participants must not have unresectable disease, N3 nodal involvement, or any evidence of distant metastatic disease (M1) at baseline assessment (suspected or confirmed)
  • Participants must not have active, known autoimmune disease
  • Participants must not have significant risk of bleeding or history of major hemorrhagic events (including gastrointestinal (GI) hemorrhage or hemorrhagic stroke)
  • Participants must not have GI or non-GI fistula, GI perforation, or intra-abdominal abscess
  • Other protocol-defined Inclusion/Exclusion criteria apply

Where in Taiwan

Also in 13 other countries, 46 sites

  • TaichungHospital not named in the registryContact: Site 0012No longer taking part
  • TainanHospital not named in the registryContact: Site 0017No longer taking part
  • TaipeiHospital not named in the registryContact: Site 0011No longer taking part
  • TaipeiHospital not named in the registryContact: Site 0216No longer taking part

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer

The 2 groups in the trial

  • Cohort A: PumitamigTreatment being tested

    Treatment: Pumitamig, Carboplatin, Cisplatin, Paclitaxel, and Pemetrexed

  • Cohort B: PumitamigTreatment being tested

    Treatment: Pumitamig, Carboplatin, Cisplatin, Paclitaxel, and Pemetrexed

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
ROSETTA Lung-220: A Phase 2, Open-Label, Multicenter, Multi-Arm Platform Study Evaluating Pumitamig and Other Novel Neoadjuvant Regimens in Participants With Resectable, Early-Stage (IIA to IIIB) Non-Small Cell Lung Cancer
Plain-language title
Tests pumitamig before surgery for early-stage lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 October 2026